Xenon Pharmaceuticals (XENE) Stock Rockets 40% on Breakthrough Epilepsy Trial Results

TLDR

• Shares of Xenon Pharmaceuticals climbed 40% following successful Phase 3 X-TOLE2 trial results showing azetukalner achieved its primary endpoint across both dosing cohorts.
• The higher 25 mg dosage reduced monthly focal onset seizure frequency by 53.2% from baseline, compared to just 10.4% in the placebo arm.
• The data exceeded performance seen in the prior Phase 2b X-TOLE trial, which demonstrated a 34.6% placebo-adjusted median reduction.
• More than half of participants receiving the 25 mg dose (54.8%) experienced at least a 50% decrease in seizure frequency.
• The company intends to submit a New Drug Application (NDA) to the FDA during Q3 2026.

Shares of Xenon Pharmaceuticals (XENE) jumped 40% Monday following the biotech company’s announcement that its Phase 3 X-TOLE2 clinical trial of azetukalner successfully achieved its primary endpoint for treating focal onset seizures. The robust data exceeded market expectations, triggering a sharp rally at market open.

Xenon Pharmaceuticals Inc., XENE

The clinical study recruited 380 adult patients suffering from highly treatment-resistant epilepsy. These individuals had previously attempted a median of five different antiseizure medications and continued to endure approximately 12.75 seizures monthly at the study’s outset.

Patients receiving the 25 mg dosage of azetukalner experienced a median reduction of -53.2% in monthly focal onset seizure frequency compared to their baseline measurements. Meanwhile, the placebo cohort registered only a -10.4% reduction. This translates to a placebo-adjusted difference of -42.7%.

This outcome carries significant weight. The previous Phase 2b X-TOLE trial had demonstrated a placebo-adjusted median reduction of -34.6% for the 25 mg cohort. The X-TOLE2 results surpassed this benchmark considerably.

The lower 15 mg dosage also delivered solid results, achieving a -34.5% median reduction versus placebo, although investor focus centered primarily on the 25 mg data.

Secondary Endpoints Also Hit

The study successfully achieved its crucial secondary endpoint as well. Among participants in the 25 mg cohort, 54.8% experienced at least a 50% reduction in monthly seizure frequency — a metric called the Responder Rate 50. This contrasted sharply with only 20.8% in the placebo group. The 15 mg cohort registered 37.6%.

Of the 332 study participants who finished the double-blind phase, 322 continued into the open-label extension portion.

The safety data remained encouraging. The most frequently reported adverse events included dizziness, headache, somnolence, and fatigue. Discontinuation rates due to adverse events stood at 14.5% for the 25 mg cohort, 4.8% for the 15 mg group, and 3.2% for placebo recipients.

What Comes Next

Xenon intends to file an NDA with the FDA for azetukalner in treating focal onset seizures during Q3 2026. Upon approval, the medication would become the first KV7 potassium channel opener commercially available for epilepsy treatment.

Analysts at Stifel observed that the trial results might prompt investors to increase their peak sales and market penetration projections for the compound.

Azetukalner offers several practical benefits compared to currently available treatments — including once-daily administration, no titration requirement, and minimal drug-drug interactions.

The X-TOLE2 findings will be shared during an oral presentation at the American Academy of Neurology (AAN) Annual Meeting scheduled for April.

Xenon is simultaneously advancing azetukalner development for depression treatment, though this indication was not addressed in Monday’s announcement.

Shares traded approximately 40% higher Monday morning, with the rally driven exclusively by the Phase 3 data release.

The post Xenon Pharmaceuticals (XENE) Stock Rockets 40% on Breakthrough Epilepsy Trial Results appeared first on Blockonomi.